CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
<< View More Conferences
2015 NANETS Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Krampitz on Therapeutic Targets in pNETs
Dr. Kunz on Potential of Immunotherapy in Neuroendocrine Tumors
Dr. Yao on the RADIANT-4 Study for NETs of Lung or GI Origin
Oncology Conference Articles
Everolimus Shows Robust Activity in Lung/GI NETs
Everolimus improved progression-free survival by 7.1 months compared with placebo in patients with lung/gastrointestinal (GI) neuroendocrine tumors, representing a 52% reduction in the risk of progression or death.
Lu-Dotatate Shows Unprecedented PFS in Midgut NETs
Lu-Dotatate demonstrated an unprecedented 79% reduction in the risk of progression or death compared with high-dose octreotide LAR in patients with progressive, metastatic midgut neuroendocrine tumors.
Novel Drug Relieves Carcinoid Syndrome Symptoms
Telotristat etiprate, a novel serotonin synthesis inhibitor, helped reduce daily bowel movements for patients with carcinoid syndrome no longer responding to standard-of-care therapies.
Combining Chemo With mTOR Inhibitors Shows Promise in pNETS
Combining the chemotherapy streptozotocin with drugs that target the mTOR pathway may be an effective way to treat pancreatic neuroendocrine tumors.
Biomarker Needed for CAPTEM Regimen in Metastatic Pancreatic NETs
The efficacy of several predictive markers previously thought to determine which patients might respond to temozolomide-based therapy could not be validated for patients with pancreatic neuroendocrine tumors.
Full Surgical Resection Should Be Performed Whenever Possible for Gastroenteropancreatic NETs
Full surgical resection of gastroenteropancreatic neuroendocrine tumors is associated with a greater than 90% survival rate at five years.
EGFR TKIs in the Adjuvant Setting in NSCLC
Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel Improves OS in Nonsquamous NSCLC
Neoadjuvant Nivolumab Plus Ipilimumab Active in dMMR Early-Stage Colon Cancer
Atezolizumab Plus Bevacizumab Shows Durable Activity in Advanced HCC
Olaparib Substantially Improves PFS as Frontline Maintenance in Ovarian Cancer
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.